|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||77.29 - 78.34|
|52-week range||56.21 - 84.49|
|PE ratio (TTM)||29.25|
|Earnings date||2 May 2018 - 7 May 2018|
|Forward dividend & yield||0.28 (0.36%)|
|1y target est||83.86|
BioScrip's (BIOS) strategy to specifically focus on core revenue mix hurts overall growth. However, the company's core infusion business remains strong.
Orthofix's (OFIX) latest deal to boost Spine Fixation portfolio and strengthen hold in the high-potential artificial disc market buoys optimism.
The acquisition of Sirtex will fortify Varian Medical's (VAR) footprint in Australia. The transaction is likely to close in late May 2018.
Medtronic, (MDT) presenting favorable results from the studies based on the CoreValve TAVR system might boost the top line, with increased uptake of the product.
Illumina (ILMN) successfully broadens base by enriching its portfolio of sequencing products and building strategic partnerships with therapeutic and diagnostic service providers.
IDEXX Laboratories (IDXX) continues to boost investor confidence in strong companion animal business along with attractive global prospects.
Orthofix (OFIX) vouches for PhysioStim's efficiency, claiming the devices to lead the U.S. market of prescribed bone growth stimulators combined with spinal fusion stimulators.
Quest Diagnostics' (DGX) upgraded long-term guidance based on its new and extended two-point strategy looks promising. However, it expresses resentment against the recent PAMA-related CMS proposal.
Sturdy performance of NuVasive's (NUVA) international business with more than 20% growth for the fifth consecutive quarter raises optimism among investors
Chimerix (CMRX) makes progress in Q4 through advancement with lead product candidate, brincidofovir. Revenues decline from lower reimbursable expenses regarding BARDA developmental contract.
We expect Henry Schien's (HSIC) partnership with Grifols to be strategically accretive to its portfolio given the rising demand for saline products in U.S. market.
Abaxis' (ABAX) strong performance in Veterinary consumables drives growth. Weak gross and operating margin scenario is a concern.